SPPI Shares Outstanding History
Below is a table of the SPPI shares outstanding history going back to 3/29/2010:

Date SPPI Shares Outstanding
3/29/201049.17M
5/3/201049.50M
8/2/201050.14M
10/22/201050.49M
2/25/201152.00M
4/22/201152.04M
7/29/201153.20M
10/19/201157.41M
2/16/201259.27M
4/20/201259.52M
7/18/201260.24M
10/26/201259.54M
2/15/201360.16M
4/29/201360.03M
8/5/201363.31M
11/14/201363.88M
2/28/201465.29M
4/28/201465.58M
7/31/201465.73M
10/31/201465.76M
2/28/201566.87M
4/30/201567.00M
7/31/201567.31M
10/31/201567.34M
2/29/201668.16M
4/29/201669.22M
7/28/201680.22M
10/31/201680.56M
2/28/201780.25M
4/24/201780.41M
7/28/201784.50M
10/31/2017100.66M
2/15/2018102.71M
4/30/2018104.06M
7/31/2018105.96M
10/31/2018106.91M
2/21/2019111.05M
4/30/2019111.96M
7/31/2019112.86M
10/31/2019112.97M
2/21/2020113.69M
4/30/2020116.47M
8/5/2020145.73M
10/31/2020145.92M
3/24/2021153.73M
5/10/2021161.52M
8/6/2021164.07M
11/8/2021163.96M
3/10/2022177.15M
5/9/2022180.09M
8/8/2022188.16M

Also see: SPPI Market Cap History
SPPI YTD Return
SPPI Historical Shares Outstanding:
+11.46% CAGR
SPPI Historical Shares Outstanding: +11.46% CAGR

Mouse over chart for data details
3/29/2010 ...8/8/2022
Spectrum Pharmaceuticals is a biopharmaceutical company. Co. is engaged in acquiring, developing, and commercializing targeted oncology therapies. Co. has two drugs in late-stage development: Eflapegrastim, which is a long-acting granulocyte colony-stimulating factor for the treatment of chemotherapy-induced neutropenia; as well as Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations. We show 51 historical shares outstanding datapoints in our coverage of SPPI's shares outstanding history.

Understanding the changing numbers of SPPI shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like SPPI versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching SPPI by allowing them to research SPPI shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree SPPI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Spectrum Pharmaceuticals (SPPI) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

SPRB Shares Outstanding History
SPRO Shares Outstanding History
SQL Shares Outstanding History
SQZ Shares Outstanding History
SRDX Shares Outstanding History
SRGA Shares Outstanding History
SRNE Shares Outstanding History
SRPT Shares Outstanding History
SRRA Shares Outstanding History
SRRK Shares Outstanding History
More Healthcare companies »

 

SPPI Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.